SYNCAR-002

N/A

Report date: 2024/06/27 11:03:49

Base Information

Drug NameSYNCAR-002

Drug Alias NameSYNCAR-002

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitorsInterleukin-2 receptor beta chain agonists

TargetsGlypican-3Interleukin-2 receptor beta chain

Therapy Area/IndicationsCarcinoma, HepatocellularNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSynthekine Inc

China Registration ClassN/A

Develop Information

Active CompaniesSynthekine Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A